• Peptidyl arginine deiminase 2 (PADI2) citrullinates arginine1810 (cit1810) present at carboxy-terminal domain of RNA polymerase II (RNAP2-CTD).
INTRODUCTION
In mammals, the RNA polymerase II carboxy-terminal domain (RNAP2-CTD) comprises 52 heptapeptide repeats, the first half of which (1-27) exhibit the consensus repeat sequence Y 1 S 2 P 3 T 4 S 5 P 6 S 7 , whereas the second half (28-52) contains deviations from this consensus (Buratowski et al., 2009; Corden et al., 2013) . Post-translational modification of the key residues at RNAP2-CTD dictate recruitment of protein complexes, that influence transcription elongation and the processing of the nascent transcripts (Jeronimo et al., 2016; Saldi et al., 2016; Harlen et al., 2017) . The CTD is evolutionary conserved and dynamic phosphorylation of Y 1 , S 2 , T 4 , S 5 , and S 7 mediates selective recruitment of protein complexes that modulate various phases of transcription (Eick et al., 2013; Zaborowska et al., 2016; Shah et al., 2018) . Systematic studies using genetics and proteomics showed that phosphorylation of S 5 and S 2 is the most frequent modification and contributes to transcription efficiency (Schüller et al., 2016; Corden, 2016) . However, modifications in non-consensus repeats have expanded the functional role of the CTD code (Voss et al., 2015; Dias et al., 2015) and recent work has focused on methylation of arginine 1810 (R1810) at repeat 31. Its asymmetrical dimethylation (me2a) by the methyltransferase CARM1 (or PRMT4) inhibits the expression of small nuclear RNAs (snRNAs) and nucleolar RNA (snoRNA) genes in human cells (Sims et al., 2011) . This reaction is inhibited by phosphorylation of CTD serine residues, suggesting that it occurs before transcription initiation. In contrast, symmetric dimethylation (me2s) of R1810 by PRMT5 leads to recruitment of the survival of motor neuron protein (SMN) and to the interaction with senataxin, that enhances transcriptional termination (Zhao et al., 2016) .
The functional significance of dynamic post-translational deimination of arginine residues in pathophysiological conditions (Slade et al., 2014; Tanikawa et al., 2018) prompted us to investigate whether this modification occurs at R1810 of RNAP2-CTD and its possible implication in transcription regulation.
Citrullination is a deimination of protein-embedded arginine, which is converted to the non-coded amino acid citrulline (Van et al., 2000; Fuhrmann et al., 2015) .
Citrullination leads to a reduction in hydrogen-bond formation, affects histone-DNA interactions and influences the chromatin organization. Citrullination also increases the hydrophobicity of proteins that affect the protein folding ability and therefore the functional activity of proteins (Vossenaar et al., 2003; Tanikawa et al., 2018) . This reaction is catalyzed by enzymes called peptidyl arginine deiminases (PADIs), which have been associated with diverse disease conditions such as thrombosis, prion disease, neurological disorders, autoimmune disease and cancer (Witalison et al., 2015; Gyorgy et al., 2006; Vossenaar et al., 2003; Baka et al., 2012) . Among PADI family members, PADI2 is the most widely expressed isoform and is also overexpressed in breast cancer, where it regulates mammary carcinoma cell migration (Mohanan et al., 2012; Cherrington et al., 2012; Horibata et al., 2017) . Citrullination of core histones has been related to the gene expression, DNA damage responses and pluripotency (Sharma et al., 2012; Tanikawa et al., 2012; Christophorou et al., 2014) , although the underlying mechanisms are largely unknown.
RNAP2-mediated gene expression starts with binding to the gene promoters of basal transcription factors that recruit RNAP2 to form the transcription pre-initiation complex. Shortly after transcription initiation, RNAP2 pauses 30-50bp downstream of the transcription start sites (TSS), and requires the activation of P-TEFb (positive transcription elongation factor b) kinase complexes to continue with the productive elongation (Marshall et al., 1995; Adelman et al., 2012; Jonkers et al., 2015 ) . Promoterproximal pausing affects the expression of many genes but is more prominent for highly expressed genes in responses to developmental and environmental stimuli (Zeitlinger et al., 2007; Core et al., 2008; Gilchrist et al., 2010; Day et al., 2016) . Recently, RNAP2
pausing was found to inhibits transcriptional initiation, indicating that paused RNAP2 first needs to be released in order to allow a new cycle of transcription inititation (Shao et al., 2017; Gressel et al., 2017) . However, despite the strong evidence of RNAP2 pausing, the nature of paused RNAP2 to allow efficient transcription still remains unclear.
Here, we report the discovery that PADI2 citrullinates the R1810 (cit1810) at RNAP2-CTD. The absence of PADI2 mediated cit1810 widely affects transcription and cell proliferation in breast cancer cells. PADI2 occupancy increases with the level of gene transcription. Further, we found that replacing wild-type RNAP2 with the R1810A mutant compromises transcription, reduces interaction with the P-TEFb complex and leads to accumulation of RNAP2 on the proximal promoter of PADI2 dependent genes. Thus, citrullination of R1810 facilitates interaction with the P-TEFb complex favoring RNAP2 pause release and promoting transcription of cell cycle genes and cell proliferation of breast cancer cells.
RESULTS

Citrullination of R1810 at RNAP2-CTD
Two arginine residues within non-consensus repeats in human RNAP2-CTD, R1603 and R1810, are conserved in vertebrates. Recently, R1810 within repeat 31 was found to be asymmetrically (Sims et al., 2011) or symmetrically (Zhao et al., 2016) dimethylated, leading to either reduced expression of snRNAs and snoRNA or to efficient transcription termination, respectively. To examine the possibility that R1810 at RNAP2-CTD could be citrullinated in cells, we immunoprecipitated nuclear extracts from the luminal breast cancer cell line T47D (Truss et al., 1995) with a citrulline antibody followed by western blot with an antibody to RNAP2. We found two specific bands migrating as the nonphosphorylated (IIA) and phosphorylated (IIO) forms of the large subunit POLR2A of RNAP2. The IIO band reacted preferentially with α-citrulline compared to the IIA band of RNAP2 ( Figure S1A ). We raised a polyclonal antibody against a 13 residues peptide centered on R1810, which was replaced by citrulline (Figure 1A top) . This antibody (α-Cit1810) was specific, as it reacted with the citrullinated peptide, but not with the wildtype, methylated (me2aR1810) or phosphorylated (S2 or S5) peptides (Figure S1B-C) and mainly recognized the phosphorylated form of RNAP2 in western blots of nuclear extracts from T47D cells (Figure 1A) . RΝΑP2−Cit1810 was detected in several other cancer cell lines derived from the breast (BT474, SKBR3, MCF7), brain (SK-N-SH, T98G), and cervix (HeLa), but not in untransformed breast epithelial cells (MCF10A) or in normal fibroblasts (Figure S1D ).
To validate that R1810 is citrullinated, we transiently transfected T47D cells with an α-amanitin resistant HA-tagged wild-type (WT r ) RNAP2 or with a R1810A r mutant of RNAP2, followed by α-amanitin treatment to deplete the endogenous RNAP2 (Figure S1 E-F). Precipitation with anti-HA antibody followed by western blot showed that the WT r RNAP2, but not the R1810A r mutant, reacts with α-Cit1810 (Figure 1B) . In superresolution immunofluorescence images of T47D cells, α-Cit1810 decorated bright clusters overlapping with RNAP2, preferentially in its S2 or S5 phosphorylated forms ( Figure 1C-D) . Thus, R1810 is citrullinated in cells prevalently on the phosphorylated actively transcribing form of RNAP2.
Citrullination of R1810 by PADI2
In a search for the responsible enzyme, we found that T47D cells express only PADI2 and PADI3 (Figure 2A ) among family members. Depletion of PADI2 but not PADI3 reduces R1810 citrullination (Figure 2B, Figure S2A ). In MCF7 breast cancer cells that express PADI2 and PADI4 (Cuthbert et al., 2004; Sharma et al., 2012) , depletion of PADI2 but not PADI4 reduced R1810 citrullination (Figure S2B-C) . To test whether PADI2 acts directly on the RNAP2-CTD we incubated recombinant PADI2 with either a recombinant GST-N-CTD (repeat 1-25.5, including R1603) or with GST-C-CTD (repeat 27-52, including R1810) ( Figure 2C , left panel). PADI2 citrullinates R1810 in the C-CTD much more efficiently than R1603 in N-CTD (Figure 2C, right panel) . Thus, PADI2 is the enzyme responsible for citrullination of R1810 in breast cancer cells
The affinity of PADI2 for the unmodified R1810 peptide measured by microscale thermophoresis (Jerabek et al., 2011) is K d =220±54.5 nM, whereas peptides phosphorylated at S2 or S5 were not bound ( Figure 2D) , suggesting that the observed S2/S5 phosphorylation in R1810 citrullinated CTD must occur outside of repeats 31 and 32. In co-immunoprecipitation experiments using T47D and MCF7 cells extracts, PADI2 but neither PADI3 or nor PADI4 interacted with RNAP2 (Figure S2D-E) . Similarly, an antibody against PADI2 precipitated Cit1810-RNAP2, along with S5P-and S2P-RNAP2 (Figure 2E, Figure S2F ). Monoclonal antibodies against RNAP2 phosphorylated at S2 and S5 (see methods) precipitated Cit1810 RNAP2 as well as PADI2 but not PADI3 ( Figure 2F) . In T47D nuclear extracts fractionated using size exclusion chromatography PADI2 eluted along with phosphorylated RNAP2 in the high molecular weight fractions, whereas PADI3 eluted in lower molecular weight range ( Figure S2G ). Finally, triple labeling immunofluorescence microscopy showed that PADI2 co-localizes with Cit1810-RNAP2 and with S2P-RNAP2 ( Figure S2H) . These observations support the association of PADI2 with Cit1810-RNAP2 that is engaged in transcription. To explore whether PADI2 was also expressed in samples from cancer patients, we analyzed the expression of PADI gene family across cancer cohorts and found that only PADI2 is overexpressed in breast and other cancers (Figure S3A -E) and that PADI2 overexpression correlates with poor prognosis (Figure S4A -E).
Citrullination of R1810 regulates transcription and cell proliferation
We next performed mRNA sequencing in control and PADI2 depleted T47D cells ( Figure S5A) . Strikingly, in global differential expression (DEseq) analysis PADI2 knockdown affected the expression of over 4,000 genes; downregulated (2,186) and upregulated (2,141) ( Figure 3A, Figure S5B ). Gene ontology analysis of the downregulated genes revealed enrichment in RNAP2-mediated transcription and cell proliferation ( Figure S5C) . Reduced expression was validated by RT-qPCR for several genes including SERPINA6, c-MYC, and HMGN1 genes, while control genes GSTT2 and LRRC39 were not affected (Figure 3B, Figure S5D ). Depletion of CARM1 or PRMT5, which catalyze dimethylation of R1810 (Sim et al., 2011; Zhao et al., 2016) , did not affect the expression of PADI2-dependent genes (Figure S5E-F) , indicating that R1810 dimethylation and citrullination affect the expression of different sets of transcripts.
To explore the direct effect of PADI2 on nascent transcription, we performed chromatin-associated RNA sequencing (ChrRNA-seq, Nojima et al., 2016) in control and PADI2 depleted cells. We found that ~2,000 transcripts were significantly affected by the PADI2 knockdown, and the majority of them were downregulated (1,884, Figure 3C -D, Figure S5G ). ChrRNA-seq changes were validated on PADI2-dependent genes by RT-qPCR ( Figure 3E ). We conclude that PADI2 is required for efficient transcription and that upregulation of mRNAs upon PADI2 depletion may be a consequence of downregulation of transcription relevant genes, although we cannot exclude citrullination of other PADI2 substrates. To support this conclusion, we performed mRNA sequencing in T47D cells expressing only the α-amanitin resistant HA-tagged WT r or the R1810A r mutant form of RNAP2. We found 1,392 down-regulated genes in cells expressing R1810A r mutant RNAP2, of which 939 (67.4%) were also dependent on PADI2. We confirmed this finding by RT-qPCR of a PADI2-dependent SERPINA6, c-MYC, and HMGN1 and control genes GSTT2 and LRRC39 (Figure 3F) . Thus, PADI2 and R1810 are required for efficient transcription. Since many PADI2-dependent genes are related to cell proliferation, we monitored T47D cell proliferation after PADI2 depletion (siPADI2), inhibition with Clamidine, or in cells expressing only the R1810A r mutant of RNAP2. In all cases, we found a significant reduction of cell numbers (Figure 3G ). PADI2-depleted cells were arrested at the G1 phase of the cell cycle ( Figure S5H) , as expected given the downregulation of genes critical for G1 phase progression including CCND1, PLK1 (Figure 3H, Figure   S5I ).
PADI2 is enriched on active genes
ChIP-seq of PADI2 in T47D cells showed that 60% of chromatin-bound PADI2 was localized over protein-coding gene sequences, within 3kb upstream of the TSS (transcription start site) and 3kb downstream of the TTS (transcription termination site) (q value ≤0.005) (Figure 4A, left panel) ). The highest enrichment (2.5-fold) was found in the coding exons, followed by the 3kb region downstream of the TTS (1.6-fold) ( Figure 4A, Right panel) ). Overall, PADI2 occupancy overlapped with RNAP2 binding measured by ChIP-seq ( Figure 4B) . To explore whether PADI2 binding is related to transcription, we separated genes in 4 quartiles according to their transcription level: high (100-95%), medium (95%-50%), low (last 50%) and silent (non-significant expression) (Baranello et al., 2016) . We found that RNAP2 and PADI2 occupancy increased in parallel with the gene expression levels (Figure 4C, Figure S6A ), supporting a role of PADI2 in transcription.
To verify the specificity of the PADI2 occupancy, we performed PADI2 ChIP-qPCR in control (siCTRL) and PADI2 knockdown (siPADI2) over high (SERPINA6, c-MYC) and low expressed (GSTT2) genes and found that PADI2 depletion drastically decreased the levels (Figure S6B ). PADI2 occupancy was significantly higher on genes downregulated by PADI2 depletion compared to those non-regulated ( Figure S6C) .
Finally, RNAP2-ChIP followed by PADI2 re-ChIP revealed the association of RNAP2 and PADI2 at regulatory regions and gene bodies of the highly transcribed SERPINA6, c-MYC genes, but not in the low expressed GSTT2 gene ( Figure S6D) . Thus, PADI2 seemed to be part of the transcription machinery in highly expressed genes.
Citrullination of R1810 controls RNAP2 pausing
To investigate the role of R1810 citrullination in transcription, we analyzed RNAP2 occupancy by ChIP-qPCR in T47D cells prior and after PADI2 depletion. We observed accumulation of RNAP2 around the TSS of the highly expressed SERPINA6, c-MYC, HMGN1 genes ( Figure 5A) . This effect is also dependent on R1810, as it is observed in T47D cells expressing only the α-amanitin resistant HA-tagged R1810A r mutant form of RNAP2 in comparison with cells expressing only the WT r RNAP2 (Figure 5B ), suggesting absence of PADI2 mediated citrullination of R1810 leads to RNAP2 pausing.
In T47D cells expressing only the R1810A mutant compared to cells expressing the WT r RNAP2, ChIP-seq experiments showed remarkably high accumulation of RNAP2 at proximal promoters (Figure 5C left panel) and a corresponding change in the pausing index that correlated with the gene expression levels (Figure 5C right panel) . Previously, Raji cells expressing R1810A also showed paused RNAP2 at proximal promoter for the 5% most highly expressed genes (Zhao et al., 2016) .
Focusing on PADI2-dependent genes (n=2186), we found a pronounced accumulation of RNAP2 around the TSS with a significantly increased pausing index in presence of R1810A mutant as compared to wild-type form of RNAP2 (Figure 5D-F) .
Similarly, genes downregulated in the presence of the R1810A r RNAP2 mutant (n=939) also showed significantly higher pausing index as compared to cells expressing WT r RNAP2 (Figure S7B) . Thus, PADI2 depletion or absence of R1810 lead to RNAP2 accumulation on the promoters of highly expressed genes and to reduced level of S2P and S5P forms of RNAP2 (Figure S7A ). We also found that genes upregulated upon depleting PADI2 or upon expressing the R1810A r mutant RNAP2 exhibited lower pausing index (Figure S7C-D) , suggesting that they do not need to overcome RNAP2 pausing to maintain their expression. In summary, we found that PADI2 citrullination of CTD R1810 is important for RNAP2 promoter pause release.
Cit1810 at RNAP2-CTD recognized by P-TFEb
Citrullination is known to modulate functional protein-protein interactions (Tanikawa et al., 2018; Tanikawa et al., 2012; Vossenaar et al., 2003) . We wondered whether the Cit1810 influences the interaction of RNAP2 with the components of P-TEFb complex CDK9 and CCNTI (Ccylin T1), which are required for RNAP2 pause release and productive elongation (Jonkers et al. 2015; Gressel et al., 2017) . Immunoprecipitation of T47D cells extracts with a PADI2 antibody, precipitated CDK9 and CCNT1 (Figure 6A) and conversely a CDK9 antibody pulled down PADI2 (Figure 6B) , indicating that PADI2 associates with the P-TEFb complex. Immunoprecipitation of extracts from PADI2 depleted cells (siPADI2) showed strong reduction in RNAP2 interaction with CDK9 and CCNT1 compared to control cells (siCTRL) (Figure 6C) . In T47D or Raji cells expressing only the α-amanitin resistant HA-tagged WT r RNAP2, CDK9 and CCNT1 were also immunoprecipitated with HA-tag antibody, and the interaction was significantly reduced in cells expressing the R1810A r mutant RNAP2 (Figure 6D-E) .
Thus, PADI2 and R1810 are required for the association of RNAP2 with the CDK9-CCNT1 complex.
To explore whether R1810 is important for CDK9 recruitment to the promoter region of genes, we performed ChIP-seq with CDK9-antibody in T47D cells expressing only the α-amanitin resistant HA-tagged R1810A r or the WT r RNAP2. We found that CDK9 occupancy around the TSS decreased remarkably in the presence of R1810A mutant compared to wild-type form of RNAP2, particularly in highly expressed genes ( Figure 6F ), suggesting that the integrity of the R1810 is required for CDK9 recruitment.
When we compared PADI2 dependent and non-dependent genes we also found a significant decrease of CDK9 occupancy in the presence of R1810A mutant as compared to wild-type form of RNAP2 ( Figure 6G) . We validated the ChIP-seq results by ChIP-qPCR and confirmed that mutation of R1810 significantly decrease the recruitment of the CDK9 to the promoter of PADI2 target genes SERPINA6, c-MYC, HMGN1, but not to the low expressed genes GSST2 and LRRC39 (Figure 6H) . Altogether, this data supports the idea that PADI2 mediated citrullination of R1810 at RNAP2-CTD facilitates the recruitment of P-TEFb complex needed that promotes polymerase pause release and transcription of highly expressed genes involved in cellular proliferation.
PADI2 unique residues contribute to citrullinate R1810 at RNAP2-CTD
We wondered about the reason why only PADI2 but not PADI3 or nor PADI4 carries out citrullination of R1810 at RNAP2-CTD. To address this issue, we used the published structure of the PADI2 (Slade et al., 2015) to model the attachment of RNAP2-CTD peptide encompassing R1810 (Figure 7A) , and performed a similar structural modeling with the amino acids of PADI3. Our analysis revealed that the predicted binding score energies calculated with Rosetta were significantly lower for PADI2 in comparison to PADI3 (Figure 7B) , indicating a higher affinity of PADI2 for the R1810 peptide.
We next examined the PADI2 residues contributing most to the affinity for the R1810 peptide and analyzed their conservation in the PADI family. We found that nonconserved residues in PADI2 accumulate at the rim of the catalytic domain, most likely contributing to the R1810 peptide binding. We calculated Rosetta score for all PADI2 interface residues (including conserved and non-conserved) and ranked them according to conservation among PADI family members. Next, we choose PADI2 specific residues R580 and L642 and also two other PADIs conserved residues D374 and S401 that showed comparable low binding energy of PADI2 toward the R1810 peptide (Figure 7A) , and introduced mutations that changed chemical properties of these four residues while maintaining the volume. Using GST C-CTD that encompasses R1810 as a substrate for in vitro citrullination assays, we found that the R580E and L642T mutations drastically reduced citrullination activity, whereas the D374K and S401A have a non-significant effect (Figure 7C) , confirming the specificity of PADI2 unique residues for citrullination of R1810.
DISCUSSION
In this study, we identify a novel post-translational modification of the RNAP2-CTD, namely the citrullination by PADI2 of R1810. This modification is coupled with the active form of RNAP2 and regulates the transcription of highly expressed genes involved in cell proliferation by mediating the interaction with P-TEFb and favoring RNAP2 pause release. We detected this modification initially in T47D breast cancer cells with a pancitrulline antibody and confirmed it with Cit1810 antibody generated using a 13-mer CTD peptide centered on Cit1810. This modification is also present in several other breast cancer cell lines (MCF7, BT747, SKBR3), in HeLa cells, and also brain cancer cell lines (SK-N-SH and T98G), but is much less abundant in untransformed fibroblasts and breast epithelial cells. In breast cancer cells, PADI2 but not PADI3 or PADI4 specifically catalyze R1810 citrullination. Inhibition or depletion of PADI2 compromises transcription of thousands of highly expressed genes, as monitored by mRNA-seq analysis. Many of these PADI2-dependent genes are involved in key biological functions including RNAP2 transcription and cell proliferation. In chromatin RNA-seq, we found that PADI2 is mainly involved in active transcription, leading us to conclude that PADI2 participates in facilitating active transcription. However, in mRNA-seq analysis we also find genes up-regulated upon PADI2 depletion. Their up-regulation could be an indirect consequence of changes in the expression of PADI2-dependent genes or could be related to the need of R1810 dimethyation for proper transcription termination . This remains to be directly demonstrated.
The previously reported asymmetrical (Sims et al., 2011) and symmetrical dimethylation of R1810 occurs mainly in hypo-phosphorylated RNAP2, as detected only after phosphatase treatment. In contrast, we find that cit1810 is preferentially associates with the transcriptionally engaged phosphorylated RNAP2.
Depletion of the methyltransferases responsible for R1810 dimethylation, CARM1 and PRMT5, did not affect the expression of PADI2 dependent genes, and depletion of PADI2 did not change the expression of a broad range of snRNAs, the targets of CARM1. As PADI2 can not act on merthylate R1810, and citrullination will preclude methylation by arginine methyltrasferases, its seems that these are alternative types of modifications influencing different stages of transcription, as observed in other arginine residues that can undergo methylation and citrullination (Tanikawa et al. 2018; Cuthbert et al., 2004) . This implies the dynamic nature of R1810 modifications, that change the docking surface for regulatory protein complexes to control various phases of transcription.
Our results of RNAP2 ChIP-seq show that PADI2 mediated cit1810 is required for RNAP2 pause release or high turnover (Krebs et al., 2017 ) at promoters of highly expressed genes that maintain cellular proliferation (Day et al., 2016; Gilchrist et al., 2010; Zeitlinger et al., 2007) . In search for the molecular mechanism, we found that PADI2 interacts with the P-TEFb kinase complex, which is needed for RNAP2 pause release and productive transcript elongation. This interaction depends on R1810, supporting a function of cit1810 to facilitate transcription. Strikingly, by modeling how the structure of PADI2 could accommodate the R1810 CTD peptide, we identified PADI2-specific amino acid residues that are not conserved in other PADI family members, and when mutated interfere with citrullination of R1810 at RNAP2-CTD.
Although our results support a function of PADI2 mediated citrullination of CTD R1810 in transcription elogation, we cannot exclude an action of PADI2 on other substrates, including citrullination arginine 26 at histone H3 (H3R26), which could be involved in local chromatin decondensation and transcription activation . Another intriguing open question concerns the implications of the proposed irreversibility of the citrullination reaction (Cuthbert et al., 2004; Wang et al., 2004) . In the absence of enzymes that erase citrullination, alternative mechanisms may exit to replace the citrullinated RNAP2 before reaching transcription termination. Given that arginine-mediated interactions between intriniscally disordered protein domains, including the CTD of RNAP2, and RNAs or Poly(ADP-Ribose) are important in the formation of liquid droplets within the cell nucleus (Altmeyer et al. 2015; Hnisz et al. 2017; Harlen et al., 2017) , we cannot exclude that citrullination of R1810 could also participate in modulating this interactions, and those influencing transcritional output.
Further work will be required to investigate these possibilities.
Many elongation factors and kinases are implicated in the control of RNAP2 transcription pause release, a mechanism that controls the expression of genes involved in cancer progression and metastasis, like CDK9, MYC, JMJD6 Bywater et al., 2013; Miller et al., 2017) . PADI2 is also found overexpressed in breast cancer and other cancers (Guo et al., 2017) . Indeed, we found that PADI2 depletion or mutation of R1810 reduced cell proliferation of breast cancer cells, by modulating cell cycle progression. Also, among PADI family members, only PADI2 is overexpressed in breast cancer and other cancers and its overexpression correlates with poor prognosis. Thus, our finding opens the possibility that specific inhibition of citrullination at R1810-RNAP2 may represent a suitable drug target for combinatorial cancer therapy. 
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(F) Western blot of extracts from cells depleted of endogenous RNAP2 by preincubation with 6µg/ml α−amanitin, and transfected with empty vector (-) or with expression vectors for WT r or the R1810A r mutant HA-tagged recombinant RNAP2 carrying an additional mutation that makes the enzyme resistant to α−amanitin (see Method). The western blots were probed with antibodies against the HA tag or total-RNAP2; Tubulin was used as loading control. Scale at the bottom is as (Figure S3A) . mRNA levels were normalized to a GAPDH mRNA expression level, which was not affected in these experimental conditions, and are presented as a ratio to levels in cells transfected siCTRL. Values are the mean ± SEM of at least three biological replicates as in other plots in the figure. (B 
